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Myotonic dystrophy type 2 (DM2) is a dominantly inherited
autosomal disease with multi-systemic clinical features and it
is caused by expansion of a CCTG tetranucleotide repeat in the
first intron of the zinc finger protein 9 (ZNF9) gene in 3q21.The
expanded-CCUG-containing transcripts are retained in the cell
nucleus and accumulate in the form of focal aggregates which
specifically sequester the muscleblind-like 1 (MBNL1) protein,
a RNA binding factor involved in the regulation of alternative
splicing. The structural organization and composition of the
foci are still incompletely known.In this study,the nuclear foci
occurring in cultured myoblasts from DM2 patients were char-
acterised at fluorescence and transmission electron
microscopy by using a panel of antibodies recognizing tran-
scription and processing factors of pre-mRNAs.MBNL1 proved
to co-locate in the nuclear foci with snRNPs and hnRNPs,
whereas no co-location was observed with RNA polymerase II,
the non-RNP splicing factor SC35, the cleavage factor CStF
and the PML protein.At electron microscopy the MBNL1-con-
taining nuclear foci appeared as roundish domains showing a
rather homogeneous structure and proved to contain snRNPs
and hnRNPs.The sequestration of splicing factors involved in
early phases of pre-mRNA processing supports the hypothesis
of a general alteration in the maturation of several mRNAs,
which could lead to the multiple pathological dysfunctions
observed in dystrophic patients.
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M
yotonic dystrophy type 2 (DM2) is a dom-
inantly inherited autosomal disease with
multi-systemic clinical features and it is
caused by expansion of a CCTG tetranucleotide
repeat in the first intron of the zinc finger protein 9
(ZNF9) gene in 3q21 (Liquori et al.,2001;Ranum
and Day, 2004). The expanded-CCUG-containing
transcripts are retained in the cell nucleus and accu-
mulate in the form of focal aggregates (Liquori et
al.,2001).These aggregates are a biomolecular fea-
ture of DMs and have been evidenced in several
adult tissues and cell cultures by in situ hybridiza-
tion (Taneja et al., 1995; Liquori  et al., 2001;
Mankodi  et al., 2003, 2005; Jiang  et al., 2004;
Schoser et al., 2004;Wheeler et al., 2007; Cardani
et al., 2004, 2009). The nuclear foci of mutant
mRNA specifically sequester muscleblind-like
(MBNL) proteins, i.e. essential splicing factors
(Pascual et al., 2006), leading to nuclear depletion
and a loss of function of these regulators (Mankodi
et al., 2001). MBNL proteins are therefore good
markers for the DM2-specific RNA-containing
nuclear aggregates (Mankodi et al., 2001; Fardaei
et al., 2002; Cardani  et al., 2006, 2009).
Sequestration of RNA binding proteins is thought to
alter the splicing of a large set of pre-mRNAs,
including transcripts of the insulin receptor, ClC-1
chloride channel, and other genes relevant to the
clinical manifestations (Mankodi et al., 2002;
Savkur et al.,2004).Margolis et al. (2006) demon-
strated that DM2 foci contain the expanded CCUG
tract with no other portions of the ZNF9 transcript.
This repetitive RNA persists in the nucleus even
after other parts of the intron have been degraded
because it has a stable secondary structure or
because it is tightly associated with binding proteins
(Dere et al., 2004; Margolis et al., 2006; Ranum
and Cooper, 2006).
The molecular composition of nuclear foci is far
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              from being fully elucidated, but it is likely to
hypothesize that other proteins involved in RNA
processing may be sequestered therein, with a pos-
sible rebound on the overall nuclear function.
The effective role of nuclear foci in DM disease
process is still debated. Recently Junghans (2009)
has published his viewpoint on this item in which he
discusses if foci may reflect the disease or if may be
causative to DM pathogenesis. Studies on molecu-
lar composition and mechanisms of formation of
nuclear foci may better explain the real role of
these aggregates in the disease process.
In eukaryotic cells,transcription and splicing take
place inside nuclear RNA-containing structures
recognized, at electron microscopy, as perichro-
matin fibrils (PF), perichromatin granules (PG),
and interchromatin granules (IG) (Spector, 1996;
Fakan,2004).PF are the morphological equivalent
of hnRNA transcription and co-transcriptional
splicing, while IG represent a storage site for small
nuclear RNPs (snRNPs) and non-snRNP splicing
factors, and PG are involved in the storage and the
nucleus-to-cytoplasm transport of mRNA (recently
reviewed in Biggiogera et al., 2007). PF and PG
locate at the periphery of condensed chromatin,and
IG in the so-called interchromatin space (for a
review, see Puvion and Puvion-Dutilleul, 1996):
this is a necessary prerequisite for the maturation
of nuclear RNAs, so that whenever transcription
and/or splicing are altered, the organization, com-
position,and intranuclear location of RNP-contain-
ing structures are affected too (Biggiogera et al.,
2004, 2007). It has been shown that transcription-
al arrest (irrespective of its physiological or
induced origin: Biggiogera et al., 2004) results in
the formation of heterogeneous ectopic RNP-
derived structures (HERDS) which contain two or
more RNP components that normally do not co-
locate (Biggiogera  et al., 1998; Biggiogera and
Pellicciari, 2000). The accumulation within
HERDS of RNA and protein factors involved in the
processing of nuclear RNAs actually blocks the
maturation and export of mRNAs.
The aim of this study was to investigate by means
of fluorescence and immunoelectron microscopy
the molecular composition of DM2 nuclear foci, in
the attempt to elucidate whether other protein
besides MBNL might be present therein.Using cul-
tured myoblasts from DM2 patients we have also
described,for the first time,the ultrastructural fea-
tures of the RNA-containing nuclear foci.
Materials and Methods
Sample collection and cell culture
The biopsies used in this study were taken, under
sterile conditions, from the biceps brachii of four
DM2 patients,after informed consent.The histolog-
ical diagnosis was performed on serial sections
processed for routine histological or histochemical
staining, based on the clinical criteria set by the
International Consortium for Myotonic Dystrophies
(Moxley  et al., 2002). The biopsies from donors
were trimmed of blood vessels, fat and connective
tissues, and rinsed in phosphate-buffered saline
(PBS); satellite cells were isolated as reported in
Cardani et al. (2009) and placed in HAM’s F10
medium (Sigma-Aldrich, Buchs, Switzerland) sup-
plemented with 15% fetal bovine serum (Gibco,
Invitrogen, Italy), 0.5 mg/mL albumin from bovine
serum (BSA, Sigma - Aldrich), 0.5 mg/mL fetuin,
0.39 µg/mL dexamethasone, 10 ng/ml epidermal
growth factor, 0.05 mg/mL insulin, 3 mg/mL glu-
cose, 100 U/mL penicillin and 100 µg/ml strepto-
mycin (Sigma - Aldrich).The myoblasts obtained by
this procedure were propagated in plastic flasks at
37°C in a humidified 95% air/5% CO2 atmosphere.
For transmission electron microscopy, the
myoblasts were fixed in the flasks and then collect-
ed by scraping, whereas for light microscopy they
were previously planted on glass coverslips to be
processed for fluorescence  in situ hybridization
(FISH) and immunocytochemistry (see below).
Fluorescence microscopy
For fluorescence in situ hybridization (FISH) and
immunocytochemistry, myoblasts were fixed with
2% formaldehyde in PBS for 30 min at 4°C.
For FISH, a Texas red labelled (CAGG)5 probe
(IDT, Coralville, IA, USA) was used as previously
reported by Cardani et al. (2004, 2009). Briefly,
fixed myoblasts were permeabilized with 2% ace-
tone in PBS (pre-chilled at -20°C) for 5 min. After
washing in PBS, sections were incubated in 30%
formamide and 2xSSC for 10 min at room temper-
ature (r.t.), and then hybridized with the probe (1
ng/µL) for 2 h at 37°C in 30% formamide,2xSSC,
0.02% BSA, 67 ng/µL yeast tRNA, 2 mM vanadyl
ribonucleoside complex. Cells were washed in 30%
formamide and 2xSSC at 45°C for 30 min,washed
five times in PBS for 3 min at r.t.,and pre-incubat-
ed with normal goat serum (DAKO, Glostrup,
Denmark) at a dilution 1:20 in PBS containing 2%
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MBNL1 protein was performed using a rabbit poly-
clonal anti-MBNL1 (kind gift of Prof. C. A.
Thornton, University of Rochester, NY, USA) at a
dilution of 1:1000 in PBS containing 2% BSA,for
2 hr at r.t., then revealed with an Alexa 488-
labelled goat anti-rabbit antibody (Molecular
Probes, Invitrogen, Italy) diluted 1:200 in PBS
containing 2% BSA for 1 h at r.t..After incubation,
the cells were stained for DNA with 165 nM 4.6
diamidino-2-phenylindole (DAPI) in PBS at r.t. for
30 min, and finally mounted with ProLong
(Molecular Probes, Invitrogen).
To get information on the intranuclear location of
the RNA-containing foci and their composition, a
panel of antibodies directed against MBNL1 or
transcription,splicing or cleavage factors were used
in dual-immunolabelling experiments (Table 1);
secondary antibodies labelled with different fluo-
rochromes were used. Briefly, 2% formaldehyde-
fixed myoblasts were post-fixed with cold 70%
ethanol, and incubated with the primary and the
appropriate secondary antibodies (for 2 h and 1 h
respectively, at r.t.); immunolabelled myoblasts
were stained for DNA with 0.1 µg/mL of Hoechst
33258 in PBS (10 min at r.t.), and finally mount-
ed in a drop of Mowiol (Calbiochem, Milan, Italy).
As negative controls, some slides were processed
as described above, but omitting the incubation
with the primary antibodies.
An Olympus BX51 microscope equipped with a
100W mercury lamp was used under the following
conditions: 330-385 nm excitation filter (excf),
400-nm dichroic mirror (dm), and 420-nm barrier
filter (bf), for Hoechst 33258 or DAPI; 450-480
nm excf, 500-nm dm, and 535 nm±20 nm band-
pass filter, for the fluorescence of Alexa 488; 540
nm excf,580 nm dm,and 620 nm bf for Alexa 594
or Texas red. Images were recorded with an
Olympus MagniFire camera system, and processed
with the Olympus CellF software (Olympus Italia
Srl, Segrate, Italy).
Transmission electron microscopy
For conventional morphology, cells were fixed
with 2.5% glutaraldehyde and 2% paraformalde-
hyde in 0.1 M Sörensen phosphate buffer at 4°C
for 1 h,washed,post-fixed with 1% OsO4 at 4°C for
30 min, dehydrated with acetone and embedded in
Epon. For immunoelectron microscopy, cells were
fixed with a mixture of 4% paraformaldehyde and
0.2% glutaraldehyde in 0.1 M Sörensen phosphate
buffer at 4°C for 1 h, washed, treated with NH4Cl
0.5 M in PBS,dehydrated with ethanol and embed-
ded in Unicryl resin.
Ultrathin sections from Epon-embedded samples
were conventionally stained with uranyl acetate and
lead citrate.
Ultrathin sections from Unicryl-embedded sam-
ples were placed on nickel grids and processed for
immunocytochemistry with the same anti-MBNL1
antibody used for fluorescence microscopy.Sections
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Table 1. Features of the antibodies used for immunofluorescence analyses. 
Antibody Origin Antigen Dilution Secondary marker Reference - Source
Anti-C8V chicken hnRNP 1:1000 Alexa 594 labelled Jones et al.,1980
polyclonal core proteins Goat anti-chicken IgG
Anti-Sm mouse  Sm antigen (U1,U 2,U 4/6,U 5 snRNP) 1:100 Alexa 594 labelled Abcam (Cambridge,UK)
monoclonal Goat anti-mouse IgG
Anti-SC35 mouse  SC-35 non snRNP 1:200 Alexa 594 labelled  Sigma Chem Co.(St.Louis MO,USA)
monoclonal splicing factor Goat anti-mouse IgG
Anti-CStF chicken Cleavage stimulation factor 1:2000 Alexa 594 labelled  Veraldi et al.,2001
polyclonal Goat anti-chicken IgG
Anti-RNA polymerase II mouse  Phosphorylated 1:100 Alexa 594 labelled  Research Diagnostics Inc.
(clone H14) monoclonal (activated) form  Goat anti-mouse IgM (Concorde MA,USA)
of RNA polymerase II
Anti-PML mouse Human PML protein 1:200 Alexa 594 labelled Santa Cruz Biotechnology
monoclonal Goat anti-mouse IgG (Santa Cruz CA,USA)were floated on normal goat serum (NGS) diluted
1:100 in PBS and incubated overnight at 4°C with
the primary antibody diluted 1:50 in a solution con-
taining 0.1% BSA and 0.05% Tween 20 in PBS.
After rinsing,sections were floated in NGS and then
reacted for 20 min with the specific gold-conjugat-
ed secondary antibody (Jackson ImmunoResearch,
West Grove, PA) diluted 1:10 in PBS. Finally, the
sections were rinsed and air dried. As controls,
some grids were treated with the incubation mix-
ture without the primary antibody and then
processed as described above.
Moreover, in order to confirm the apparent co-
location of MBNL1 with some splicing factors as
observed by immunofluorescence microscopy (see
the section Results), myoblast samples were also
dual-immunolabelled by combining the anti-
MBNL1 antibody with antibodies directed against
either the Sm complex of U1, U2, U5 and U4/U6
snRNPs (Abcam,Cambridge,MA) or the heteroge-
neous nuclear RNP (hnRNP) core protein (Jones
et al., 1980), according to the procedure described
above.
To reduce chromatin contrast and selectively
reveal nuclear RNP constituents, the sections were
treated according to the EDTA method (Bernhard,
1969), and then observed in a Philips Morgagni
TEM operating at 80kV and equipped with a
Megaview II camera for digital image acquisition.
Results
Fluorescence microscopy
In DM2 myoblasts, MBNL1 proved to be present
in discrete dots (which correspond to the expanded-
CCUG-containing foci: Figure 1) as well as in a
weakly fluoresceing diffused form throughout the
nucleoplasm (consistent with the intranuclear loca-
tion of splicing factors). Dual immunolabelling
experiments demonstrated that MBNL1 does not
co-locate in the foci with the non-snRNP splicing
factor SC35 (Figure 2) and the PML protein
(Figure 3); similar results were obtained also for
RNA polymerase II and the cleavage factor CStF
(not shown).
On the contrary, the hnRNP core protein (Figure
4) and the snRNP Sm antigen (Figure 5) were
observed in some of the MBNL1-positive foci.
Interestingly enough,the immunolabelling for these
RNPs appeared as a ring-shaped fluorescence pat-
tern around the brightly fluoresceing MBNL1-con-
taning core (insets of Figure 4 and 5). In addition,
some co-location for the hnRNP core protein and
for the Sm antigen was also observed to occur also
in the nucleoplasm (Figure 4 and 5).
Fluorescent labelling was negligible in the nega-
tive controls (not shown).
Transmission electron microscopy
At electron microscopy, myoblast nuclei showed
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Figure 1. In the myoblast nuclei, the immunolabelling for MBN1 (green fluorescence in a) and the signal of in situ hybridization for the
mutant mRNA containing CCUG repeats (red fluorescence in b) co-locate (yellow fluorescence in the merged image, c). DNA was coun-
terstained with DAPI (blue fluorescence). Bar: 10 µm.155
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Figure 2. The immunolabelling for MBNL1 (green fluorescence in a) and that for the non-snRNP splicing factor SC35 (red fluorescence in
b) do not co-locate (merged image, c). DNA was counterstained with Hoechst 33258 (blue fluorescence in a, b). Bar: 10 µm.
Figure 3. The immunolabelling for MBNL1 (green fluorescence in a) and that for the PML protein (red fluorescence in b) do not co-locate
(merged image, c). DNA was counterstained with Hoechst 33258 (blue fluorescence in a, b). Bar: 10 µm.
Figure 4. The immunolabelling for MBNL1 (green fluorescence in a) and that for the hnRNP core protein (red fluorescence in b) co-locate
(yellow fluorescence in the merged image, c). DNA was counterstained with Hoechst 33258 (blue fluorescence in a, b). Bar: 10 µm. In
the insets, the co-labelled focus indicated by the arrow is shown at a higher magnification.
Figure 5. The immunolabelling for MBNL1 (green fluorescence in a) and that for the snRNP Sm antigen (red fluorescence in b) co-locate
(yellow fluorescence in the merged image, c). DNA was counterstained with Hoechst 33258 (blue fluorescence in a, b). Bar: 10 µm. In
the insets, the co-labelled focus indicated by the arrow is shown at a higher magnification.small condensed chromatin clumps (mainly at the
nuclear periphery), PG and abundant PF preferen-
tially located at the hedge of condensed chromatin,
and small clusters of IG in the interchromatin
space; the nucleoli were large with a few fibrillar
centres surrounded by the dense fibrillar compo-
nent and a prominent granular component (Figure
6). In addition to the usual structural constituents,
roundish nuclear domains (100-200 nm in diame-
ter) were observed in about 20% of the sectioned
nuclei: in Epon-embedded samples they appeared
as roundish homogeneously strong electron-dense
structures (Figure 4), while in the Unicryl-embed-
ded and EDTA-treated samples they appeared as
less electron-dense irregularly sized domains sur-
rounded by fine fibrils spreading out at their periph-
ery (Figure 7). They always occurred in the inter-
chromatin space. The gold-immunolabelling for
MBNL1 specifically occurred on PF and was found
to accumulate in the nuclear domains described
above (Figure 7a). Consistent with the evidence in
fluorescence microscopy, MBNL1 was observed to
co-locate in the foci with hnRNPs (Figure 7b) and
with the snRNP Sm antigen (Figure 7c). On the
thin sections, however, the gold grains labelling
these RNPs were distributed all over the foci and
not at the periphery only.
Background values were negligible in all immuno-
labelling experiments (not shown).
Discussion
Combining fluorescence and immunoelectron
microscopy on DM2 cultured myoblasts, we
obtained information on the molecular composition
of the typical nuclear foci were the expanded-
CCUG-containing transcripts accumulate; in addi-
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Figure 6. Myoblast nucleus, glutaraldehyde fixation, OsO4 post-
fixation, Epon embedding. A strongly electron-dense roundish
nuclear domain (arrow) occurs in the nucleoplasm. Ch: con-
densed chromatin; Nu: nucleolus. Bar: 1 µm.
Figure 7. Myoblast nuclei, paraformaldehyde fixation, Unicryl-
embedding, EDTA staining. (a) Immunolabelling with anti-MBNL1
antibody: the signal accumulates in the RNP nuclear domain
(arrows) and is also associated with PF (arrowheads). (b) Dual
immunolabelling with anti-MBNL1 (12 nm) and anti-snRNP (6
nm) antibodies; (c) dual immunolabelling with anti-MBNL1 (18
nm) and anti-hnRNP (12 nm) antibodies: in both cases the
probes co-locate in the RNP nuclear domain (arrow) and on PF
(arrowheads). Bars: 250 nm (a-c); 100 nm (insets). tion these foci were recognized as distinct nuclear
domains at the ultrastructural level.
Experiments of simultaneous in situ hybridization
and immunolabelling confirmed that in cultured
myoblasts the mutant RNA-containing nuclear foci
sequester the splicing factor MBNL1 (Cardani et
al., 2009), thus indicating that the molecular fea-
tures observed in DM2 adult tissues are reproduced
in  in vitro muscle cells (Mankodi et al., 2003;
Cardani et al., 2004; Schoser et al., 2004).
The RNA-containing nuclear foci observed at flu-
orescence microscopy can be also recognized at
electron microscopy as roundish electron-dense
domains which do contain RNPs (as demonstrated
by the EDTA regressive staining), and proved to be
immunopositive for MBNL1. These nuclear
domains are always surrounded by PF but never
occur in proximity of IG clusters, consistent with
previous observations by immunofluorescence tech-
niques (Holt et al., 2007). They morphologically
resemble the so-called amorphous bodies, i.e.,
RNP-containing nuclear aggregates which accumu-
late in several Vertebrate tissues during hiberna-
tion, and are storage sites for many protein factors
involved in pre-mRNA processing (e.g., Malatesta
et al., 1994, 1999, 2006). The diffuse immunola-
belling for MBNL1 observed in myoblast nuclei at
fluorescence microscopy was found to correspond
to the ultrastructural labelling of PF, where tran-
scription and early splicing of pre-mRNA take place
(Fakan, 2004); this distribution is in agreement
with the functional role of  MBNL1 as an RNA-
binding protein involved in the regulation of alter-
native splicing (Pascual et al.,2006).Fluorescence
dual-immunolabelling experiments demonstrated
that RNA polymerase II, the non-snRNP splicing
factor SC35, the cleavage factor CStF, and the
PML protein do not co-locate with MBNL1 in the
foci, whereas a co-occurrence herein was observed
for the hnRNP core protein and the snRNP Sm
antigen. This co-location was confirmed by immu-
noelectron microscopy not only on the RNP-con-
taining nuclear domains but also on PF; this latter
finding corresponds to the diffuse co-location
observed at light microscopy. Interestingly, in elec-
tron micrographs the labelling for hnRNPs and
snRNPs was distributed over the whole nuclear
domains, whereas at fluorescence microscopy a
bright ring-shaped signal for hnRNPs or snRNPs
was found to surround the MBNL1-rich core of the
foci.To explain this inconsistence, one should con-
sider that at electron microscopy the antibodies can
interact with their antigens even inside the foci,
since the immunolabelling is performed on sections;
on the contrary, whole cells are used for the
immunofluorescent labelling, so that the penetra-
tion of the probe could be hindered by the apparent-
ly dense structure of the RNP-containing foci.The
intense fluorescence for hnRNPs and snRNPs
around the foci could also be explained by the high
content in these two splicing factors on PF which
surround the MBNL1-containing core. The pres-
ence of hnRNPs and snRNPs indicates that the
DM2-specific nuclear foci share similarities in their
molecular composition with both the amorphous
bodies and the HERDS, i.e., the heterogeneous
aggregates containing at least two nuclear RNA-
associated protein factors which usually do not co-
locate. Amorphous bodies form during hibernation,
when the transcription and splicing rate is drasti-
cally reduced, and disassemble upon arousal,
releasing the pre-mRNA processing factors accu-
mulated therein, in order to rapidly resume the
nuclear activities (Malatesta et al.,2001).HERDS
were observed in different cell systems, whenever
RNA transcription is altered, and have been sug-
gested as a possible marker of transcriptional
arrest (Biggiogera and Pellicciari, 2000): under
normal conditions, a balance exists between the
amount of newly synthesized pre-mRNA and the
proteins involved in their processing but, if the
amount of newly formed hnRNA decreases, RNA-
associated proteins become exceedingly predomi-
nant and accumulate in HERDS. The present
results suggest that an exceeding amount of RNA
(i.e., the expanded-CCUG-containing transcripts
retained in the nucleus of DM2 cells) can determine
the sequestration in the foci not only of MBNL1
but also of other pre-mRNA processing factors.
Some of the pathological features of DM are
thought to be caused by the mis-regulated alterna-
tive splicing of RNA due,at least in part,to the mis-
localization of MBNL1 (review in Osborne and
Thornton, 2006).The sequestration of other splic-
ing factors involved in early phases of pre-mRNA
processing demonstrated by the present study
strengthens the idea of a general alteration in the
maturation of several mRNAs, which could lead to
the multiple pathological dysfunctions observed in
dystrophic patients.The occurrence of hnRNPs and
snRNPs in some (but not all the) RNA-containing
foci suggests that a possible limiting factor for their
157
Original Papersequestration could be the amount of CCUG
repeats and/or MBNL1 accumulated therein; tak-
ing into account that the severity of the DM2 phe-
notype relates to the amplification of tetraplet
repeats, this opens interesting perspectives for
future studies.
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